D
Dayra Therapeutics
Oral macrocyclic peptide therapeutics for various diseases
About Dayra Therapeutics
Dayra Therapeutics is a biotechnology company launched in 2024, focused on developing oral macrocyclic peptide therapeutics to treat a range of serious diseases. The company was founded by the venture capital firm Versant Ventures, emerging from its Frontier Discovery Engine, a research and development incubator located in Toronto and Montreal. Dayra's leadership includes Rami Hannoush, Ph.D., a venture partner at Versant, serving as acting CEO, and Roger Palframan, Ph.D., as Chief Scientific Officer.
The company's core technology combines a macrocycle discovery platform with computational design and modeling. This approach aims to create novel, orally administered macrocyclic peptides that can selectively target disease-relevant proteins. This class of medicine has the potential to offer the high specificity and efficacy of biologic drugs, which are typically injectable, but with the convenience of an oral pill. The technology is designed to access protein binding sites that are challenging for traditional small molecule drugs to reach.
Upon its launch, Dayra Therapeutics secured over $70 million in committed capital. A cornerstone of its initial financing is a major research collaboration with Biogen Inc. Under this partnership, Biogen provided a $50 million upfront payment for Dayra to identify, validate, and optimize oral macrocycle candidates for high-priority immunological targets. The business model involves Biogen advancing these molecules through further development, manufacturing, and potential commercialization. Biogen holds the option to acquire each development candidate, which would trigger additional payments to Dayra, along with potential preclinical and clinical development milestones for each program.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 24.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Drug Development, Immune System, Biotech and Pharma, AI Drug Discovery, CompBio, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Nov 2025 | $70M | $280M | Versant Ventures | ↗ |
Growth signals
Latest recorded traffic for Dayra Therapeutics is 300 monthly website visits, down 6.3% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Dayra Therapeutics in the San Francisco ecosystem
The Dayra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dayra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dayra Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








